<DOC>
	<DOC>NCT00592839</DOC>
	<brief_summary>This is a multi-center study to evaluate the effects of SCE-B on nocturnal vasomotor symptoms. Study duration will be approximately 16 weeks; this includes a 4-week screening period and approximately 5 scheduled clinic visits. Participants will receive one of two strengths of SCE-B tablets plus matching placebo or placebo only, and will have a physical and gynecological exams that may include transvaginal ultrasound, endometrial biopsy and a pap smear. Participants will be asked to wear a monitoring device for a portion of the study and be asked to complete a daily dairy.</brief_summary>
	<brief_title>Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estrogens, conjugated synthetic B</mesh_term>
	<mesh_term>Estrogens, conjugated synthetic A</mesh_term>
	<criteria>Naturally or surgically menopausal Minimum 7 daily or 50 weekly moderatetosevere hot flashes Any contraindication to hormone therapy</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Nocturnal vasomotor symptoms in postmenopausal women</keyword>
</DOC>